Visit our new Alternative Investment section.Click here

Less Ads, More Data, More Tools Register for FREE

PRESS: Soriot commits to five more years as AstraZeneca CEO - Times

Wed, 25th Oct 2023 11:04

(Alliance News) - Pascal Soriot has committed to remaining as chief executive officer of AstraZeneca PLC for another five years, The Times reported on Wednesday.

Soriot, who is 64 years old, made the remark following the European Society for Medical Oncology congress in Madrid over the weekend, the newspaper said.

Soriot hopes that, when he does depart AstraZeneca, an internal candidate will replace him, saying it would be "a failure on my part if I'm not replaced by someone on my team", according to the Times.

https://www.thetimes.co.uk/article/astrazeneca-boss-sir-pascal-soriot-commits-to-another-five-years-at-the-top-vbxjmw03f

Soriot has been CEO of AstraZeneca since October 2012. The company's share price has more than tripled during those 11 years, giving it a market capitalisation of GBP161.54 billion.

The stock was up 0.5% at 10,490.00 pence on Wednesday morning in London.

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Astrazeneca

Shares in this article

Related News

US Supreme Court rebuffs pharma challenge to Biden-era drug price
18 hours ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

* Companies say government has dictated below-market prices

Citi sees buying opportunity at AstraZeneca after recent falls
21 hours ago

Citi sees buying opportunity at AstraZeneca after recent falls

(Sharecast News) - Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-...

US regulator greenlights AstraZeneca's blood pressure drug Baxfendy
23 hours ago

US regulator greenlights AstraZeneca's blood pressure drug Baxfendy

(Alliance News) - AstraZeneca PLC on Monday reported US clearance for its hypertension treatment Baxfendy.